News

Press Releases

Verseau Therapeutics Announces FDA Clearance of Investigational New Drug Application for VTX-0811, a PSGL-1 Targeting Monoclonal Antibody
January 4, 2022

Verseau Therapeutics Appoints Karen Tubridy as Chief Development Officer
September 7, 2021

Verseau Therapeutics Appoints John Edwards as Chief Executive Officer
May 26, 2021

Verseau Launches with $50 Million to Develop First-in-Class Macrophage-Targeted Immunotherapies
October 21, 2019

3SBio and Verseau Establish Global Clinical Development Collaboration for First-in-class Immuno-Oncology Therapies
February 11, 2019

Presentations and Publications

Macrophages: A New Frontier For Treating Solid Tumours
November 16, 2021

PSGL-1 blocking antibodies repolarize tumor associated macrophages, reduce suppressive myeloid populations and induce inflammation in the tumor microenvironment, leading to suppression of tumor growth
November 10, 2021

Targeting VSIG4, a novel macrophage checkpoint, repolarizes suppressive macrophages which induces an inflammatory response in primary cell in vitro assays and fresh human tumor cultures
November 10, 2021

Verseau Presents Data to Support Importance of Targeting PSGL-1 to Suppress Tumor Growth at Society for Immunotherapy of Cancer’s (SITC)
November 9, 2020